Why Belite Bio, Inc’s (BLTE) Stock Is Down 6.54%
As of Wednesday, July 08, Belite Bio, Inc’s BLTE share price has dipped by 6.54%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Commentary & Analysis
Why Belite Bio, Inc’s (BLTE) Stock Is Down 7.56%
As of Tuesday, June 02, Belite Bio, Inc’s BLTE share price has dipped by 7.56%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Belite Bio, Inc’s (BLTE) Stock Is Down 5.61%
As of Friday, April 10, Belite Bio, Inc’s BLTE share price has dipped by 5.61%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Belite Bio, Inc’s (BLTE) Stock Is Up 6.33%
As of Tuesday, March 31, Belite Bio, Inc’s BLTE share price has surged by 6.33%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Belite Bio, Inc’s (BLTE) Stock Is Down 6.21%
As of Monday, March 02, Belite Bio, Inc’s BLTE share price has dipped by 6.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | BLTE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,221.6 | $519.2 | 71% |
|
| Shares Out (Mil) | 36.2 | 42.8 | 41% |
|
| Institutional Ownership | 92.2% | 82.8% | 61% |
|
| Float (Mil) | 19.6 | 44.4 | 28% |
|
| Beta | -1.22 | 0.71 | 1% |
|
| Avg Daily Volume (000s) | 154 | 394 | 41% |
|
| Price Change (52-week) |
97.9% | 60.2% | 94% |
|
| Growth | BLTE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (68.0%) | (2.0%) | 4% |
|
| EPS (5yr) | (28.8%) | 15.0% | 9 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 29.0% | (15.1%) | 85% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.769) | ($2.936) | $2.260 | |
| Month Ago EPS | ($0.769) | ($2.936) | $1.924 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.817) | ($3.284) | $0.944 | |
| Year/Year Chg | 10.0% | 26.9% | (394.4%) | |
| Financials | BLTE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($78) | ($11) | 13% |
|
| EPS (TTM) | ($2.314) | ($0.700) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($37) | ($7) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 12% |
|
| Enterprise Value (Q1) (Mil) | $5,509 | $494 | 64% |
|
| Valuation | BLTE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.89 | 2.31 | 87% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BLTE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (17.7%) | (22.2%) | 21% |
|
| ROE | (18.0%) | (21.4%) | 24% |
|
| Liabilities to Assets | 1.3% | 32.8% | 0% |
|
| F-Score | 4 | 3 | 33% |
|
Belite Bio, Inc did not pass any screens on 10/9/2026.
